Comparison of Erector Spinae Plane Block and Intravenous Analgesic in Nefrectomy

March 14, 2021 updated by: Zehra Ipek ARSLAN, Kocaeli University

Erector Spinae Plane Block for Nefrectomy

The efficacy of erector spinae plane block versus intravenous analgesics compared relate to the morphine consumptions

Study Overview

Detailed Description

Patients undergoing elective nefrectomy were enrolled. Patients divided into two groups with a sealed envelope technique to ESP+ pca morphine group or iv analgesic + pca morphine group. All patients will premedicated. then esp will applied to one group before surgery at the preoperative care unit by the same anesthesiologist. The other group will receive intravenous tramadol 1 mg/kg + NSAID 1 ampule + parol 10 mg/ kg + ondansetron 4 mg bolus. İntravenous morphine pca with a concentration of 0.5 mg/cc were applied. And administered 1 mg boluses every 15 minutes lock time and 4 hour limit as 4 mg arranged. An anesthesia nurse who is responsible of all pcas' in the hospital was recorded the variables of these patients in the service

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kocaeli, Turkey
        • Kocaeli University Medical Faculty

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:18-65 years age

  • ASA I-II
  • undergoing elective nephrectomy

Exclusion Criteria:- ASA>3

  • heart disease
  • pregnancy
  • lung disease
  • scoliosis
  • bleeding disorder
  • infection at the manipulation side

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: postoperative opiod (morphine) consumption
patient-controlled analgesia (15 minutes. lock time, 2 ml bolus= total 1 mg morphine intravenously, limited to maximum 4 bolus / per hour )
erector spinae plane block applied in this group before open nephrectomy
intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
Active Comparator: peroperative continuous opioid (remifentanil) consumption
continuous remifentanil infusion was given during the whole procedure
erector spinae plane block applied in this group before open nephrectomy
intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
Active Comparator: postoperative numerated rating scale
at the 1, 3, 6, 12 and 24 th hour postoperatively - numerated rating scale score was evaluated and recoded as 0= no pain (better), 10: unbearable pain (worse)
erector spinae plane block applied in this group before open nephrectomy
intarvenous analgesic administered in this group for analgesia end of the open nephrectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative intravenous morphine patient controlled analgesia consumption
Time Frame: during postoperatively
morphine consumptions were recorded till 24 th hour postoperatively
during postoperatively
Peroperative remifentanyl consumption
Time Frame: Peroperatively
Amount of Remifentanyl consumption recorded
Peroperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual analog rating scores
Time Frame: during postoperative surgery
pain scores were recorded during surgery
during postoperative surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 30, 2020

Primary Completion (Actual)

March 10, 2021

Study Completion (Actual)

March 10, 2021

Study Registration Dates

First Submitted

December 7, 2020

First Submitted That Met QC Criteria

December 23, 2020

First Posted (Actual)

December 29, 2020

Study Record Updates

Last Update Posted (Actual)

March 16, 2021

Last Update Submitted That Met QC Criteria

March 14, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe